Puja Sapra is Executive Director at the Oncology Research and Development, Pfizer, where she leads the research group responsible for preclinical development of targeted therapeutics including nanomedicines, bioconjugates and antibody drug conjugate (ADCs). Her group has built novel sophisticated technologies to develop ADC molecules and has advanced several of these candidate molecules to clinical trials. Prior to joining Pfizer, she led Pharmacology groups at Enzon Pharmaceuticals and Immunomedics Inc. and developed oncology-based drugs that are undergoing clinical evaluation. She has broad expertise in targeting strategies including immunotherapeutics, liposomal drug delivery system, nanoparticles, antisense oligonucleotide delivery and pegylation technologies. Puja Sapra received a Bachelors degree from All India Institute of Medical Sciences, an MS in Pharmacology from UK and a PhD in Pharmacology from University of Alberta, Canada. She is an author of >50 scientific publications, book chapters and co-inventor on several issued patents.